New fast test to diagnose bacterial endophthalmitis

Article

A newly-developed fast real-t PCR (f-real-t PCR) test is an effective and much more rapid way to diagnose bacterial endophthalmitis (BE), concluded a study published online ahead of print by the British Journal of Ophthalmology.

A newly-developed fast real-t PCR (f-real-t PCR) test is an effective and much more rapid way to diagnose bacterial endophthalmitis (BE), concluded a study published online ahead of print by the British Journal of Ophthalmology.

Pablo Goldschmidt, of the Laboratoire du Centre National d’Ophtalmologie des Quinze-Vingts, France, and colleagues examined specimens of vitreous fluid (VF) and aqueous humour (AH) cells from endophthalmitis, infected with bacteria or non-infective disorders and control to determine if the f-real-t PCR testing method they had developed could overcome the barriers most commonly associated with BE testing, including insufficient VF or AH, PCR cross-contamination and culture insensitivity, to identify the bacteria and Genera of the DNA that had been extracted from the specimen cells. The team compared the diagnoses with those from direct microscopic examination and culture.

The f-real-t PCR showed no cross-reactivity with fungi even though it detected ≥0.01 CFU Bac/µl and had a 100% correlation with culture positive results. Of the BE samples, 60% tested culture positive; with f-real-t PCR, this was 90%. Within 90 minutes, the f-real-t PCR detected and quantified the presence of Bac, Staphylococci, Streptococci, Haemophilus, Pseudomonas, Enterobacteria, Acinetobacter, Propionbacteriacae and Corynebacteria. The non-infective cells tested negative.

The team therefore concluded that their f-real-t PCR test reduced substantially the hours or even days required for cultures, and provided a more accurate result. The test’s developers now plan to run a larger series of samples to assess the utility of the test.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.